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INTRODUCTION
Relapse of chronic myeloid leukemia (CML) after allo-
geneic bone marrow transplantation results from persistence
of leukemia cells that survive the pretransplantation condi-
tioning regimen and escape the graft-versus-leukemia (GVL)
e ffects mediated by donor T cells [1-3]. Treatment with α-
i n t e rf e ron can produce a complete response in 25% to 57%
of patients with re c u rrent CML after transplantation, but
BCR/ABL transcripts are still detected in most patients who
respond to this therapy [4,5]. Disease pro g ression may be
delayed by treatment with α- i n t e rf e ron, but few, if any,
patients are cured [4-6]. A second transplantation can cure
the disease but is associated with high risks of morbidity and
m o rtality [7].
Donor T cells that recognize recipient minor histocom-
patibility antigens initiate both graft-versus-host disease
(GVHD) and GVL reactions [8-13]. Donor leukocyte infu-
sion (DLI) has induced complete remission in appro x i-
mately 65% of patients with re c u rrent CML after marro w
transplantation [14-26,35]. GVHD and aplasia represent the
major complications after DLI, occurring in more than 50%
and 20% of patients, re s p e c t i v e l y, and leading to mort a l i t y
in approximately 20% of patients [24,25]. 
In this re p o rt, we present the results of 2 sequential stud-
ies of DLI in patients with CML who relapsed after unmodi-
Granulocyte Colony-Stimulating Factor Given to Donors
Before Apheresis Does Not Prevent Aplasia in Patients
Treated With Donor Leukocyte Infusion for Recurrent
Chronic Myeloid Leukemia After Bone Marrow
Transplantation
Mary E.D. Flowers, Wendy Leisenring, Kathy Beach, Stanley Riddell, Jerald P. Radich, Celestia S. Higano,
Scott D. Rowley, Thomas R. Chauncey, William I. Bensinger, Jean E. Sanders, Claudio Anasetti, 
Rainer Storb, James Wade, Frederick R. Appelbaum, Paul J. Martin
Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine, University of
Washington, Seattle, Wa s h i n g t o n
C o rrespondence and reprint requests: Mary E.D. Flowers, MD, 1100 Fairview Ave. North, FM-252, 
Seattle, WA 98109-1024; e-mail: mflowers@fhcrc . o rg
(Received October 1, 1999; accepted Febru a ry 16, 2000)
ABSTRACT
We conducted 2 sequential studies of donor leukocyte infusion (DLI) in 26 patients with chronic myeloid leukemia in
hematologic relapse after unmodified allogeneic bone marrow transplantation. In the first study, cells for DLI were
collected from 13 donors who were not treated with granulocyte colony-stimulating factor (G-CSF) (group 1). In the
second study, cells were collected from 13 donors who received G-CSF before apheresis (group 2) in an attempt to
avoid aplasia after DLI. Patients in group 2 received 550-fold more CD34+ cells than those in group 1. We found no
s i g n i ficant diff e rence in the incidence (31% versus 22%), onset time (41 vs. 48 days), or duration (15 vs. 14 days) of
cytopenia after DLI in the 2 groups. G-CSF given to donors before collection of cells did not prevent aplasia. These
findings support the hypothesis that the pathogenesis of aplasia after DLI is not restricted to the destruction of re c i p i-
ent hematopoietic cells but also involves failure of donor hematopoiesis by undefined mechanisms. 
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fied marrow transplantation. In the first study, cells used for
DLI were collected from donors who were not treated with
g r a n u l o c y t e - m a c rophage colony-stimulating factor (G-CSF)
( g roup 1). In the second study, cells were collected fro m
donors who received G-CSF before apheresis (group 2) to
i n c rease the availability of donor CD34+ p rogenitor cells in
an attempt to avoid aplasia after DLI. In this study, infusing a
high number of donor CD34+ cells did not prevent aplasia
after DLI in relapsed CML patients.
PATIENTS AND METHODS
Patients were treated with DLI at the Fred Hutchinson
Cancer Research Center (FHCRC) between June 1991 and
August 1997. All patients and donors signed consent forms
approved by the Institutional Review Board. Treatment with
i m m u n o s u p p ressive medications was discontinued at least
14 days before DLI. Patient characteristics are shown in
Table 1. All patients received DLI for treatment of CML in
hematologic relapse after allogeneic hematopoietic stem cell
transplantation. Patients with new cytogenetic abnormalities
that developed during treatment with interf e ron and
patients with classical clinical features of disease progression
were categorized as having accelerated phase CML.
In the first study, all patients initially received a single
infusion of cells obtained from the original donor by
apheresis on 1 or 2 days. The intended cell dose of the first
DLI was 1.5 × 1 08 CD3 cells/kg for patients with HLA-
matched related donors and 0.1 × 1 08 CD3 cells/kg for
patients with unrelated or HLA-mismatched related donors.
If no response, no GVHD, and no aplasia were observed, a
second infusion of cells was given 60 days after the first
DLI—sooner in patients with progressive CML in acceler-
ated or blast phase. 
In the second study, donors were treated with G-CSF
at a dose of 16 µg/kg per day for 4 days before aphere s i s
on day 5. Unrelated donors were excluded from this study.
The first 5 patients were enrolled in a dose de-escalation
trial that was not restricted to patients with CML. The
first 5 patients in that trial were infused with all cells col-
lected during a single apheresis. The study design speci-
fied that if the lower limit of the 1-sided 90% confidence
i n t e rval for the incidence of grades III to IV GVHD was
g reater than 20%, the CD3 cell dose in the next group of
patients was reduced to 50% of the median cell dose for
the first group. Further 50% reductions in the CD3 cell
dose were applied according to the same rule for subse-
quent groups of patients.
Two patients in the first study and 5 in the second study
with CML in blast phase were treated with induction
chemotherapy before DLI.  The median time fro m
c h e m otherapy to DLI was 22 days (range, 2-70 days).
Patients received diff e rent regimens of induction chemo-
therapy depending on their history and disease morphol-
o g y. Chemotherapy regimens included vincristine, pre d-
nisone with or without anthracyclines or L- a s p a r a g i n a s e
( n = 3); etoposide (100 mg/m2 qd on days 1-5) and mitox-
antrone ( 1 0 m g / m2 qd on days 1-3) (n = 2); cytosine ara-
binoside (1.5 mg/m2 bid on days 1, 3, and 5), daunorubicin
(45 mg/m2 qd on days 1-3), vincristine, and prednisone (n =
1); and cytosine arabinoside (100 mg/m2 qd on days 1-7) and
daunorubicin (45 mg/m2 qd on days 1-3) (n = 1). 
For chimerism studies before and after DLI, peripheral
blood leukocytes and bone marrow cells were tested either
by flu o rescence in situ hybridization with X and Y chro m o-
s o m e – s p e c i fic probes or by analysis of informative variable
number tandem repeat markers [27]. If no donor- d e r i v e d
T cells could be detected in the blood, patients were excluded
f rom DLI because rejection could not be ruled out. Assess-
ment of acute and chronic GVHD was made according to
clinical and histologic criteria re p o rted previously [28,29].
For at least 3 months, patients were followed weekly for
signs and symptoms of GVHD. Screening studies for
c h ronic GVHD were perf o rmed 3 months after DLI [30].
Cytopenia was defined as an absolute neutro p h i l
count ≤ 5 0 0 / m m3 or a platelet count ≤50,000/mm3 w i t h i n
3 months after DLI and not explained by medication or
other causes. Patients who had cytopenia at the time of DLI
w e re not evaluable for cytopenia after DLI but were
included in these studies to evaluate other end points. 
Table 1. Patient Characteristics at Time of Treatment According to 
Treatment Group*
Donor Received G-CSF
Before Apheresis
No Yes
(Group 1) (Group 2)
n 13 13
Chronic myeloid leukemia phase
Chronic 4 (31) 5 (38)
Accelerated 7 (54) 3 (23)
Blast 2 (15) 5 (38)
Age, y 35 (11-60) 44 (23-60)
Donor type
HLA-identical sibling 8 (61) 12 (92)
HLA-mismatched relative 1 (8) 1 (8)
Unrelated 4 (31) 0 (0)
Donor/recipient sex
Female/female 1 (8) 2 (15)
Female/male 0 (0) 1 (8)
Male/female 2 (15) 2 (15)
Male/male 10 (77) 8 (61)
Percent donor cells before DLI† 20 (0-75) 35 (0-100)
Months from transplant
To relapse 23 (3-83) 30 (2.4-92)
To first DLI 47 (7.2-100) 44 (3.7-124)
Interferon treatment before DLI 9 (69) 8 (61)
Months of interferon treatment 18 (2-51) 13 (2-24)
Induction chemotherapy before DLI 2 (15) 5 (38)
Days from chemotherapy to DLI 47 (25-70) 9 (2-44)
Cycles of DLI
1 8 (61) 8 (61)
2 5 (38) 5 (38)
Days between DLI cycles 63 (35-309) 65 (21-105)
Cells infused per kilogram 
patient weight
Mononuclear cells 3 10 –8 (n = 24) 3.5 (0.2-8.4) 6.4 (3.6-13.2)
CD3 + 3 10 –8 (n = 20) 1.0 (0.1-2.6) 2.0 (1.0-3.7)
CD34 + 3 10 –6 (n = 17) 0.01 (0.01-0.46) 5.5 (0.3-13.8)
*Data are n (%) or median (range). DLI indicates donor leukocyte
infusion; G-CSF, granulocyte colony-stimulating factor.
†Marrow cells or peripheral blood granulocytes.
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Complete response after DLI was defined as norm a l
blood cell counts, 100% donor chimerism, and the absence
of cytogenetic abnormalities in the marrow with at least 20
metaphases analyzed. Bone marrow evaluation included
molecular tests for BCR/ABL mRNA at monthly interv a l s
until 3 months after DLI or longer if response did not occur
during that time. Thereafter, bone marrow and blood sam-
ples were tested at 3- to 6-month intervals for the first year
and then yearly.
Results of this study were analyzed according to
whether the DLI product was obtained from donors who
were not (group 1) or were (group 2) treated with G-CSF
b e f o re apheresis. Survival probability was estimated using
the method of Kaplan and Meier, and comparisons were
made with log rank statistics [32].
RESULTS
All patients in this study had hematologic relapse of
CML after unmodified allogeneic marrow transplantation.
M o re than 60% of the patients had received tre a t m e n t
with α- i n t e rf e ron before DLI. In these cases, either tre a t-
ment with α- i n t e rf e ron produced no response (n = 11) or
the disease showed evidence of pro g ression during contin-
ued treatment after an initial response (n = 6). The median
duration of treatment with α- i n t e rf e ron was 15 months
(range, 2-51 months).
Cells used for DLI were collected from donors who
were not (group 1) or were (group 2) treated with G-CSF
before apheresis. Characteristics of the 2 groups were gen-
erally similar except that group 1 contained fewer patients
with CML in blast phase and unrelated donors did not
receive G-CSF (Table 1). As expected, patients in group 2
received much higher numbers (550-fold) of CD34+ c e l l s
than those in group 1 (Table 1). 
Six of 22 patients (27%) developed cytopenia after DLI,
4 in group 1 and 2 in group 2 (Table 2). Characteristics of
patients who developed cytopenia after DLI in the 2 groups
are displayed in Table 3, and the clinical outcome for these
patients is presented in Table 4. Three patients in group 1
and 1 in group 2 had marrow examined at the time of
cytopenia. Histopathologic evaluation showed severe hypo-
plasia or aplasia in all 4 cases. Two patients in group 1 and
both patients in group 2 re q u i red platelet transfusions.
T h ree patients in group 1 and both in group 2 re c e i v e d
G -CSF for management of neutropenia. We found no
s i g n i ficant diff e rence in the incidence, onset time, or duration
of cytopenia after DLI in the 2 groups. Our ability to detect
d i ff e rences between the 2 groups was limited by the small
numbers of patients in these studies. We found no correla-
tion between the percentage of recipient-derived marro w
cells or peripheral blood granulocytes before DLI and the
occurrence of aplasia after DLI. The risk of aplasia was sim-
ilar in patients who were treated with interferon before DLI
(5 of 17) and in those who were not (1 of 5) (P = 1.0). 
Table 2. Patient Outcome According to Treatment Group*
Donor Given G-CSF
Before Apheresis
No Yes
(Group 1) (Group 2)
n 13 13
Aplasia 4/13 (31) 2 /9 (22)†
Complete cytogenetic response 7/12 (58) 5/11 (45)
Chronic phase 3/4 (75) 3/5 (60)
Accelerated phase 3/7 (43) 1/3 (33)
Blast phase‡ 1/1 (100) 1/3 (33)
GVHD 7/13 (54) 7/12 (58)§
Skin 4 6
Liver 3 4
Oral cavity 3 4
Eyes 1 3
Gastrointestinal tract 3 1
Lungs 1 1
Days from first DLI to GVHD 45 (20-183) 47 (12-71)
*Data are [n with indicated outcome]/[n in category] (%), n, or median
(range). DLI indicates donor leukocyte infusion; G-CSF, granulocyte
colony-stimulating factor; GVHD, graft-versus-host disease.
†Four patients had pancytopenia before DLI and could not be eval-
uated for aplasia.
‡Three patients in blast phase could not be evaluated for response: 1
patient died on day 9 after DLI (group 2), and 2 patients (1 in each
group) with lymphoid blast phase had no evidence of CML after chemo-
therapy and before DLI.
§One patient who died on day 9 after DLI could not be evaluated for
GVHD and aplasia.
Table 3. Characteristics of Patients Who Developed Aplasia After Donor Leukocyte Infusion*
Patient Donor Given G-CSF Disease Phase Months of Interferon % Donor Cells Number of Donor
Number Before Apheresis at DLI Before DLI Before DLI† MNC, 3 10 –8/kg
2475 No Accelerated 40 85, w 4.7
2840 No Accelerated 7 50, w 5.5
5699 No Chronic 18 40, w 1.2
4747 No Accelerated 0 0, g‡ 1.8
6036 Yes Accelerated 2 1, g‡ 6.2
6977 Yes Chronic 5 15, g 5.6
*DLI indicates donor leukocyte infusion; G-CSF, granulocyte colony-stimulating factor; MNC, mononuclear cells.
†Not all patients had identical samples tested for chimerism analysis: w indicates results of testing lysed whole blood; g indicates results of testing
granulocytes recovered from Ficoll bottom layer. 
‡Chimerism results from blood T cells were 5% to 10% donor origin in patient 4747 and 75% donor origin in patient 6036.
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Even though the primary purpose of our analysis was to
d e t e rmine whether the risk of aplasia could be reduced by
the use of G-CSF–mobilized cells, we also evaluated other
outcomes in the 2 groups. The proportions of patients with
complete cytogenetic response were similar in the 2 groups
( Table 2). Of interest, responses were observed in 9 of
1 7 patients with relapsed CML that previously either pro-
gressed or did not respond to α-interferon treatment. In all
but 2 patients, responses were documented by absence of
BCR/ABL re a rrangement with an assay that could detect
P h+ cells at a frequency between 1.0 × 1 0– 5 and 1.0 × 1 0– 6
[31]. In 2 patients, BCR/ABL rearrangement persisted after
DLI (group 2). In both patients, marrow samples have
remained Ph– by conventional cytogenetic tests, and blood
cell counts have remained normal for more than 1 year after
DLI. Responses were durable in all patients, with a median
follow up of 29 months (range 7 to 50). Complete molecular
response was documented in 7 of 12 patients (58%) in group
1 and in 3 of 11 patients (27%) in group 2 (P = .21).
The incidence of graft-versus-host disease (GVHD)
was similar in the 2 groups (Table 2). Symptoms re s e m b l e d
acute GVHD alone in 7 patients, chronic GVHD alone in
5, and both acute and chronic GVHD in the remaining 6.
Two patients developed bronchiolitis obliterans. One of
them died with pulmonary failure more than 2 years after
DLI. The other, alive more than 3 years after DLI, does
not re q u i re systemic immunosuppressive drugs and has a
K a rnofsky score of 100%. One patient with prior autoim-
mune hepatitis and 3 patients with hepatitis C virus infec-
tion had exacerbation of hepatitis with concomitant GVHD
of the liver after DLI. One of them died with hepatic fail-
u re and cytomegalovirus pneumonia 3 months after DLI,
and the other 3 are alive with Karnofsky scores of 90% to
100% more than 1, 2, and 4 years after DLI. Excluding
patients with CML in blast phase, the probability of sur-
vival after DLI was similar in the 2 groups (P = .22). Causes
of death after DLI are summarized in Table 5 and were
similar in the 2 gro u p s .
DISCUSSION
In the current study, we sought to test the hypothesis that
aplasia after DLI is caused entirely through contact-depen-
dent recognition and destruction of recipient hematopoietic
cells by the same donor T cells that eliminate leukemia cells.
Some investigators have suggested that aplasia might occur
m o re frequently in patients with a low percentage of donor
cells than in those with a high percentage of donor cells
b e f o re DLI [20,21]. If this hypothesis is correct, then aplasia
should be preventable by using DLI products containing high
numbers of donor hematopoietic stem cells (CD34+ c e l l s )
capable of repopulating the recipient while re c i p i e n t - d e r i v e d
m a rrow cells are being destroyed by donor T cells.
We found that the incidence, onset time, and duration of
aplasia after DLI were not altered by infusing G-CSF–mobi-
lized peripheral blood stem cells that can produce rapid
hematopoietic reconstitution after myeloablative therapy [33].
Our findings support the hypothesis that the pathogenesis of
aplasia in CML patients after DLI is not restricted to the
d e s t ruction of recipient hematopoietic cells but also involves
f a i l u re of donor hematopoiesis by undefined mechanisms.
W h e reas the destruction of leukemic and recipient hemato-
poietic cells by donor T cells can be explained by contact-
dependent recognition and cell-mediated cytotoxicity, we spec-
ulate that destruction or inhibition of donor hematopoietic
cells after DLI may be caused by cytokine-mediated bystander
i n j u ry or by damage to marrow stroma in the recipient. Binder
et al. [34] re p o rted that excessive production of tumor necro s i s
f a c t o r-α and interf e ro n -γ by activated CD8 cells in marro w
can cause aplasia in mice. In our study, aplasia was re v e r s i b l e
and was followed by complete re c o v e ry of donor hemato-
poiesis, except for 1 patient in group 2 who died early with
sepsis and GVHD after a second DLI for treatment of disease
p ro g ression (Table 4). This observation suggests that the
Ta b le 4. Outcome in Patients With Aplasia After Donor Leukocyte Infusion*
Patient Days to Days of Marrow Acute or Complete
Number Aplasia† Aplasia‡ recovery Chronic GVHD Remission Outcome (Karnofsky Score)
2475 29 17 Yes 4/extensive Yes Died of GVHD >23 months in CR
2840 65 9 Yes 3/extensive Yes Alive >54 months, GVHD resolved (100%)
5699 54 14 Yes 0/limited Yes Alive >55 months, GVHD resolved (100%)
4747 20 16 Yes 3/extensive Yes Alive >27 months, GVHD resolved (90%)
6036 38 15 Yes/No¶ 4/NE No Died of sepsis and GVHD at 4.7 months
6977 61 14 Yes 3/NE Yes Died of hepatitis B and GVHD 2.8 months in CR
*CR indicates complete remission; GVHD, graft-versus-host disease; NE, not evaluable. 
†From donor leukocyte infusion.
‡After a second donor leukocyte infusion for treatment of disease progression.
¶Normal karyotype and negative BCR/ABL transcripts by reverse transcription–polymerase chain reaction.
Table 5. Causes of Death After Donor Leukocyte Infusion*
Number of Patients,
day of death after DLI
Group 1 Group 2
Disease progression 2 (315 and 524) 4 (48-732)
GVHD 1 (708) 1 (51)
Hepatic failure/CMV — 1 (86)
Sepsis/aplasia/GVHD — 1 (145)
*CMV indicates cytomegalovirus; DLI, donor leukocyte infusion;
GVHD, graft-versus-host disease.
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mechanisms involved in aplasia after DLI might affect mature
d o n o r-derived hematopoietic progenitors while sparing the
most immature donor-derived hematopoietic stem cells. Alter-
n a t i v e l y, the cytokine-mediated injury or stromal damage
resulting in cytopenia after DLI might be self-limited once the
stimulus responsible for activation of donor cells disappears. 
In our studies, all patients had hematologic evidence of
re c u rrent CML, and the 27% overall rate of cytopenia
after DLI was comparable to results for similar patients in
other series [22,35]. Some investigators have re p o rted that
cytopenia after DLI is rare when the evidence for re c u r-
rent malignancy is limited to persistence of Philadelphia
c h romosome documented by cytogenetic or molecular
analysis alone [24,35]. In patients with cytogenetic or
molecular abnormalities as the only evidence of re c u rre n t
m a l i g n a n c y, the recognition of a very small number of
recipient cells by donor T cells might not generate a local
cytokine response in the marrow sufficient to damage
donor hematopoietic cells.
Published reports indicate that mononuclear cells from
G-CSF–mobilized blood differ both quantitatively and qual-
itatively from unmobilized cells [36-39]. Specifically, both
the frequency and the phenotype of monocytes is altere d
such that they diminish the alloresponsiveness of T cells by
blocking utilization of the CD28 signaling pathway [38,39].
It is possible that these functional diff e rences could aff e c t
clinical outcome after DLI. Our studies were not designed
to assess differences in response rate, occurrence of GVHD,
or survival in patients treated with DLI using G-CSF–mobi-
lized or unmobilized cells. Information about these out-
comes will require additional clinical trials with large num-
bers of patients. In comparing the results of our studies,
there was a trend suggesting that the use of G-CSF–mobi-
lized cells for DLI may be associated with a lower probabil-
ity of complete molecular response. Given this potential
c o n c e rn and the fact that aplasia was not prevented, our
results provide no support for using G-CSF–mobilized cells
for DLI in patients with CML. 
Our results confirm that DLI can induce durable
responses in a large pro p o rtion of patients with re c u rre n t
CML after hematopoietic stem cell transplant. More o v e r,
our findings demonstrate that DLI can induce responses in
m o re than 50% of patients even when previous tre a t m e n t
with α- i n t e rf e ron was unsuccessful. Additional studies are
needed to provide further insight into the mechanisms of
antileukemia effects, GVHD, and aplasia after DLI.
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